<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02785562</url>
  </required_header>
  <id_info>
    <org_study_id>GFPC 06-2015</org_study_id>
    <nct_id>NCT02785562</nct_id>
  </id_info>
  <brief_title>Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression.</brief_title>
  <acronym>EXPLORE-PDL1</acronym>
  <official_title>Epidemiologic Multicenter Prospective Study in Advanced NSCLC Patients With PDL1 Expression : Evaluation of Clinical and Pathological Characteristics of PDL1 High Expression Patients Compared to Patients With a Weak or no Expression of PDL1.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francais De Pneumo-Cancerologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Francais De Pneumo-Cancerologie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epidemiologic multicenter prospective study in advanced NSCLC patients with PDL1 expression :
      evaluation of clinical and pathological characteristics of PDL1 high expression patients
      compared to patients with a weak or no expression of PDL1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Few data are published on the clinical and pathological characteristics of advanced NSCLC
      with high PDL1 expression compare to weak and no expression populations.

      There is not for the moment a standard test to determine a relevant target population.
      Preliminary data showed that around 25% of the NSCLC population may have a high PDL1
      expression and may have a greater benefit of anti PDL1 therapy. But in fact limited data have
      been published in European populations on the clinical and pathological characteristics (high
      PDL1 expression) compared to the weak expression and no expression populations. More over the
      prognosis rule of a high PDL1 expression in NSCLC is not definitive, with some studies
      indicating it is a positive prognostic factor while other studies showing that it is a
      negative prognostic factor.

      To understand if there are differences in terms of prognostic between advanced NSCLC with
      high and low/no expression of PDL1 is a major challenge for the future management strategy of
      these patients. The results of this study should helps to elaborate new guidelines for this
      population. Therefore is also important to had data's on the natural course of the disease in
      these population for building cost effectiveness models of new immune therapies.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>description of the PDL1 expression groups as follows : PDL1 negative, PDL1 positive, PDL1 weak, PDL1 strongly positive.</measure>
    <time_frame>24 Months</time_frame>
    <description>Descriptive and comparative analyses of different sub-populations will be performed with qualitative and quantitative variables. Quantitative variables will be described using the following descriptive statistics: sample size, number of missing values, mean, standard deviation, median, minimum and maximum.
Qualitative variables will be described using the following descriptive statistics: sample size, number of missing values and percentage of each modality calculated from the responses expressed.
The bivariate statistical analyses performed will be subjected to statistical tests, based on the nature of the variables analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical characteristics of PDL1 high expression patients compared to patients with a weak or no expression of PDL1.</measure>
    <time_frame>24 Months</time_frame>
    <description>Descriptive and comparative analyses of different sub-populations will be performed with qualitative and quantitative variables. Quantitative variables will be described using the following descriptive statistics: sample size, number of missing values, mean, standard deviation, median, minimum and maximum.
Qualitative variables will be described using the following descriptive statistics: sample size, number of missing values and percentage of each modality calculated from the responses expressed.
The bivariate statistical analyses performed will be subjected to statistical tests, based on the nature of the variables analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathological characteristics of PDL1 high expression patients compared to patients with a weak or no expression of PDL1.</measure>
    <time_frame>24 Months</time_frame>
    <description>Descriptive and comparative analyses of different sub-populations will be performed with qualitative and quantitative variables. Quantitative variables will be described using the following descriptive statistics: sample size, number of missing values, mean, standard deviation, median, minimum and maximum.
Qualitative variables will be described using the following descriptive statistics: sample size, number of missing values and percentage of each modality calculated from the responses expressed.
The bivariate statistical analyses performed will be subjected to statistical tests, based on the nature of the variables analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical analysis of the patients' outcome : measure of Overall Survival (OS).</measure>
    <time_frame>24 Months</time_frame>
    <description>Descriptive and comparative analyses of different sub-populations will be performed with qualitative and quantitative variables. Quantitative variables will be described using the following descriptive statistics: sample size, number of missing values, mean, standard deviation, median, minimum and maximum.
Qualitative variables will be described using the following descriptive statistics: sample size, number of missing values and percentage of each modality calculated from the responses expressed.
The bivariate statistical analyses performed will be subjected to statistical tests, based on the nature of the variables analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune characteristics of high PDL1 expression, concordance between PDL1 expression and description of immune environment measured through density of the intra tumoral Cluster of differentiation 8+ lymphocyte T cell (CD8+ Tcells/mDC).</measure>
    <time_frame>24 Months</time_frame>
    <description>The density of tumoral T cells will be described in the overall population and each subgroup through descriptive statistics. The Chi2 test will be used to assess the significance of the difference between the different subgroups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of the patients measured at each cycle of therapy thanks to EuroQol Group 5-Dimension Self-Report Questionnaire score (EQ5D questionnaire).</measure>
    <time_frame>24 Months</time_frame>
    <description>A descriptive analysis of the answers to the EQ5D will be performed. Evolution of the EQ5D profile will be evaluated. Exploratory analyzes of various risk factors of impaired quality of life will be realized. The proportion of patients reporting &quot;no&quot;, &quot;some&quot;, or &quot;extreme&quot; EQ5D health state profiles at pre-specified time points will be described.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of the Health Care Resource Use (HCRU) associated to the management of the patients thanks to EQ5D (EuroQol Group 5-Dimension Self-ReportQuestionnaire score) questionnaire.</measure>
    <time_frame>24 Months</time_frame>
    <description>Health Care Resource Use consumption will be measured associated to EQ5D questionnaire answers.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Assessment of PDL1 expression</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Other : assess clinical and pathological characteristics of PDL1 expression in Non Small Cell Lung Cancer patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assessment of PDL1 expression</intervention_name>
    <description>Intervention : 2 biopsy slides will be analyzed in central laboratory.</description>
    <arm_group_label>Assessment of PDL1 expression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 years or more

               -  With locally advanced stage (IIIb) to stage IV NSCLC - Non Small Cell Lung Cancer
                  -

               -  Histological diagnostic :

          -  No known Epidermal Growth Factor Receptor (EGFR) or Anaplastic Lymphoma Kinase (ALK) /
             Reactive Oxygen Species (ROS) translocation

          -  At least 2 slides of tumoral sample available

               -  No previous chemotherapy treatment. Neo or adjuvant therapy is allowed if done at
                  least one year before inclusion

               -  Performance Status ( PS) 0/1

        Planned to receive a platin based standard treatment (cisplatin or carboplatin with
        bevacizumab (restricted to no squamous) pemetrexed(restricted to no squamous) ,
        gemcitabine, vinorelbine, docetaxel or taxol, on first line setting, in standard dose

        â€¢ A RECIST - Response Evaluation Criteria In Solid Tumor - target lesion

        Exclusion Criteria:

          -  Age fewer than 18

          -  Pregnancy

          -  Known immune deficit

          -  PS &gt; 1

          -  Inclusion in a clinical therapeutic trial in first line

          -  Patient treated with Protein D1/Protein Death Ligang1 (PD1/PDL1) therapy on first line
             setting.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christos CHOUAID, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>FCPC Vice President</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christos CHOUAID, Professor</last_name>
    <phone>33 (0) 1 57 02 20 70</phone>
    <email>christos.chouaid@chicreteil.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alain VERGNENEGRE, Professor</last_name>
    <phone>33 (0) 5 55 05 66 29</phone>
    <email>alain.vergnenegre@unilim.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier D Argenteuil</name>
      <address>
        <city>Argenteuil</city>
        <state>Val D'oise</state>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 12</name>
      <address>
        <city>Aix En Provence</city>
        <zip>13100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 22</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 48</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 33</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 04</name>
      <address>
        <city>GAP</city>
        <zip>05000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Les Oudairies</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire DUPUYTREN</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 19</name>
      <address>
        <city>Perigueux</city>
        <zip>24019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 18</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 11</name>
      <address>
        <city>Villefranche Sur Saone</city>
        <zip>69655</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008 Nov 10;26(32):5275-83. doi: 10.1200/JCO.2008.17.8954. Epub 2008 Oct 6. Review.</citation>
    <PMID>18838703</PMID>
  </results_reference>
  <results_reference>
    <citation>Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331. Review.</citation>
    <PMID>18173375</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>May 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2016</study_first_posted>
  <last_update_submitted>May 27, 2016</last_update_submitted>
  <last_update_submitted_qc>May 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PDL1 expression : Protein Death Ligand 1 expression .</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://www.g-f-p-c.org</doc_url>
      <doc_comment>The login can be obtained directly on gfpc site.</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

